Pancreatic Cancer Research

ResearcherHunan Normal UniversityActive in the last 2 years

Xu Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9681-1630; OpenAlex author ID A5100385689. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 6 papers · 2024: 1 paper

Papers 9

  1. Prognostic and therapeutic value of the Eph/Ephrin signaling pathway in pancreatic cancer explored based on bioinformatics. Co-author DOI 10.1038/s41598-024-68385-9↗
  2. A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo. Co-author DOI 10.1007/s10142-023-01158-1↗
  3. Integrated single-cell and bulk RNA sequencing revealed the molecular characteristics and prognostic roles of neutrophils in pancreatic cancer. Co-author DOI 10.18632/aging.205044↗
  4. Identifying endoplasmic reticulum stress-related molecular subtypes and prognostic model for predicting the immune landscape and therapy response in pancreatic… First author DOI 10.18632/aging.205094↗
  5. PANoptosis-related molecular subtype and prognostic model associated with the immune microenvironment and individualized therapy in pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1217654↗
  6. Identification and characterization of interferon-γ signaling-based personalized heterogeneity and therapeutic strategies in patients with pancreatic cancer. Co-author DOI 10.3389/fonc.2023.1227606↗
  7. Endoscopically guided interventional photodynamic therapy for orthotopic pancreatic ductal adenocarcinoma based on NIR-II fluorescent nanoparticles. Co-author DOI 10.7150/thno.84164↗
  8. Characterization of neuroendocrine regulation- and metabolism-associated molecular features and prognostic indicators with aid to clinical chemotherapy and imm… Co-author DOI 10.3389/fendo.2022.1078424↗
  9. Circulating leptin and adiponectin levels in patients with pancreatic cancer. Co-author DOI 10.1097/cm9.0000000000001509↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qihang Yuan · 6 shared papers, 2021–2024 · strength 1.08
  2. Biao Zhang · 5 shared papers, 2021–2023 · strength 0.87
  3. Dong Shang · 4 shared papers, 2021–2023 · strength 0.70
  4. Zhizhou Wang · 3 shared papers, 2022–2023 · strength 0.53
  5. Shuang Li · 3 shared papers, 2021–2023 · strength 0.49
  6. Fangyue Guo · 2 shared papers, 2023 · strength 0.37
  7. Xueying Shi · 2 shared papers, 2023 · strength 0.37
  8. Shilin Xia · 2 shared papers, 2023 · strength 0.37
  9. Dong Shang · 2 shared papers, 2022–2023 · strength 0.34
  10. Bing Qi · 1 shared paper, 2024 · strength 0.22
  11. Dong Shang · 1 shared paper, 2024 · strength 0.22
  12. Jifeng Liu · 1 shared paper, 2024 · strength 0.22
  13. Shuang Li · 1 shared paper, 2024 · strength 0.22
  14. Hui Guo · 1 shared paper, 2023 · strength 0.19
  15. Huiyi Song · 1 shared paper, 2023 · strength 0.19
  16. Hangyu Liu · 1 shared paper, 2022 · strength 0.16
  17. Hong‐Wen Liu · 1 shared paper, 2023 · strength 0.15
  18. Sulai Liu · 1 shared paper, 2023 · strength 0.15
  19. Ning Zhou · 1 shared paper, 2023 · strength 0.15
  20. Yan Liao · 1 shared paper, 2023 · strength 0.15
  21. Kang Chen · 1 shared paper, 2023 · strength 0.15
  22. Guosheng Song · 1 shared paper, 2023 · strength 0.15
  23. Wei Cheng · 1 shared paper, 2023 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.